tiprankstipranks
Trending News
More News >

AbCellera assumed with an Outperform at Leerink

Leerink assumed coverage of AbCellera (ABCL) with an Outperform rating and $5 price target The firm likes AbCellera’s pivot from being an antibody discovery platform company to developing their own internal pipeline, and it sees potential for ABCL575 in atopic dermatitis and ABCL635 in vasomotor symptoms. Both programs are up-and-coming agents with validated mechanisms in large commercial opportunities.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1